Immune responses to influenza vaccination in lupus patients receiving high and low immunosuppressive agent lupus high dose influenza vaccine seroprotection seroconversion
Conditions
Interventions
Booster dose quadrivalent inactivated influenza vaccine (two seperated standard dose injection 4-12 weeks apart) administered intramuscular route in both high and low immnosuppressive lupus patients,S
Booster dose influenza vaccination,Standard dose influenza vaccination
Sponsors
Mahidol university
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Lupus patients diagnosed by the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE Classification criteria, 2. Under the care of rheumatologists at the rheumatology clinic of Ramathibodi Hospital
Exclusion criteria
Exclusion criteria: 1. Pregnancy, 2. Active cancer, 3. Positive HIV status, 4. Prior history of organ transplant, 5. Receipt of influenza vaccine or prior history of an influenza infection within six months, 6. Evidence of CMV infection within three months, 7. Known history of severe allergic reaction to influenza vaccine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seroprotection, seroconversion 4-12 weeks after vaccination Hemagglutination inhibition assay | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of influenza infection within 6 months after end of the intervention Questionnaire interview,Adverse events after vaccination within 72 hours after vaccination Common Terminology Criteria for Adverse Events (CTCAE) version 5 | — |
Countries
Thailand
Contacts
Public ContactSasicha Yingyounyong
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed